MetaCap

Equillium (EQ) vs Nkarta (NKTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Equillium (EQ) has outperformed Nkarta (NKTX) over the past year, gaining 10.4% versus a loss of 36.9%. Over five years, EQ leads with a -80.4% price change compared with -93.0% for NKTX. Equillium is the larger company by market cap ($87.3 million vs $81.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EQ+10.42%NKTX-36.94%
+247%+98%-51%
Nov 21, 20251 yearNov 20, 2026
EQ-79.81%NKTX-93.47%
+11%-44%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EQ versus NKTX key metrics
MetricEQNKTX
Share price$1.06$1.14
Market cap$87.26M$81.29M
1-day change-5.36%+1.34%
YTD return-31.61%-38.65%
1-year return+10.42%-36.94%
5-year return-80.41%-93.05%
EPS (TTM)$-0.12$-1.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-22.40M$-104.08M
52-week high$3.54$3.72
52-week low$0.81$1.11
Distance from 52-week high-70.06%-69.49%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+707.55%+825.11%
Average volume544.39K1.02M
Shares outstanding82.32M71.62M
Employees14108
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • EQ has outperformed NKTX by 47.4 percentage points over the past year.

About Equillium

EQ stock →

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Nkarta

NKTX stock →

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.

Health Care · Biotechnology: Pharmaceutical Preparations · 108 employees

EQ vs NKTX FAQ

Which is bigger, Equillium or Nkarta?

Equillium (EQ) is larger, with a market capitalization of $87.26M compared with $81.29M for Nkarta (NKTX).

Which stock has performed better over the past year, EQ or NKTX?

EQ returned +10.42% over the past 12 months, compared with -36.94% for NKTX (price return, excluding dividends). Past performance does not predict future results.

Are Equillium and Nkarta in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons